Apollomics (APLM) Competitors $6.76 +1.44 (+27.07%) Closing price 05/21/2025 03:52 PM EasternExtended Trading$6.80 +0.04 (+0.52%) As of 05/21/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APLM vs. PULM, CYTH, KALA, CASI, ENLV, BCAB, ABVC, CLNN, ALXO, and NNVCShould you be buying Apollomics stock or one of its competitors? The main competitors of Apollomics include Pulmatrix (PULM), Cyclo Therapeutics (CYTH), KALA BIO (KALA), CASI Pharmaceuticals (CASI), Enlivex Therapeutics (ENLV), BioAtla (BCAB), ABVC BioPharma (ABVC), Clene (CLNN), ALX Oncology (ALXO), and NanoViricides (NNVC). These companies are all part of the "pharmaceutical products" industry. Apollomics vs. Pulmatrix Cyclo Therapeutics KALA BIO CASI Pharmaceuticals Enlivex Therapeutics BioAtla ABVC BioPharma Clene ALX Oncology NanoViricides Pulmatrix (NASDAQ:PULM) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment, institutional ownership and community ranking. Which has more risk and volatility, PULM or APLM? Pulmatrix has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. Comparatively, Apollomics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Do insiders & institutionals believe in PULM or APLM? 11.8% of Pulmatrix shares are owned by institutional investors. Comparatively, 19.1% of Apollomics shares are owned by institutional investors. 0.6% of Pulmatrix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is PULM or APLM more profitable? Apollomics has a net margin of 0.00% compared to Pulmatrix's net margin of -96.51%. Apollomics' return on equity of 0.00% beat Pulmatrix's return on equity.Company Net Margins Return on Equity Return on Assets Pulmatrix-96.51% -45.97% -30.72% Apollomics N/A N/A N/A Does the MarketBeat Community prefer PULM or APLM? Pulmatrix received 192 more outperform votes than Apollomics when rated by MarketBeat users. However, 80.00% of users gave Apollomics an outperform vote while only 48.04% of users gave Pulmatrix an outperform vote. CompanyUnderperformOutperformPulmatrixOutperform Votes19648.04% Underperform Votes21251.96% ApollomicsOutperform Votes480.00% Underperform Votes120.00% Which has better valuation and earnings, PULM or APLM? Pulmatrix has higher revenue and earnings than Apollomics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPulmatrix$7.81M2.87-$14.12M-$3.34-1.84Apollomics$1.22M6.11-$172.60MN/AN/A Does the media refer more to PULM or APLM? In the previous week, Pulmatrix had 5 more articles in the media than Apollomics. MarketBeat recorded 5 mentions for Pulmatrix and 0 mentions for Apollomics. Apollomics' average media sentiment score of 0.00 beat Pulmatrix's score of -0.04 indicating that Apollomics is being referred to more favorably in the news media. Company Overall Sentiment Pulmatrix Neutral Apollomics Neutral SummaryApollomics beats Pulmatrix on 7 of the 13 factors compared between the two stocks. Get Apollomics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLM vs. The Competition Export to ExcelMetricApollomicsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.88M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E RatioN/A8.9226.8419.71Price / Sales6.11253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book0.146.466.794.50Net Income-$172.60M$143.98M$3.23B$248.18M7 Day Performance46.00%2.03%1.53%0.20%1 Month Performance13.16%4.11%10.05%12.37%1 Year Performance-76.29%-2.87%16.71%7.04% Apollomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLMApollomicsN/A$6.76+27.1%N/A-78.7%$5.88M$1.22M0.0045PULMPulmatrix0.3673 of 5 stars$6.50+0.3%N/A+206.5%$23.73M$7.81M-2.4620Earnings ReportAnalyst ForecastGap UpCYTHCyclo TherapeuticsN/A$0.72flat$0.95+31.8%N/A$23.72M$870,725.00-0.809KALAKALA BIO3.5208 of 5 stars$3.64-0.8%$15.00+312.1%-42.7%$23.49M$3.89M-0.2930Positive NewsGap UpCASICASI Pharmaceuticals3.9385 of 5 stars$1.91-1.7%$4.00+109.7%-37.9%$23.46M$28.54M-0.86180Earnings ReportAnalyst ForecastAnalyst RevisionENLVEnlivex Therapeutics2.0603 of 5 stars$0.99-1.0%$10.00+910.1%-34.3%$23.41MN/A-1.0170News CoverageBCABBioAtla2.0058 of 5 stars$0.40+1.0%$5.00+1,137.0%-83.6%$23.38M$11M-0.2460Gap DownABVCABVC BioPharma0.1955 of 5 stars$1.38-6.8%N/A+10.2%$23.15M$508,384.00-1.6030Gap DownCLNNClene2.5288 of 5 stars$2.63+2.3%$40.00+1,420.9%-66.2%$23.09M$350,000.00-0.50100ALXOALX Oncology3.2288 of 5 stars$0.43-1.4%$3.54+720.8%-97.0%$23.03MN/A-0.1440Analyst ForecastNNVCNanoViricidesN/A$1.46+3.5%N/A-33.6%$22.84MN/A-2.0320Gap Up Related Companies and Tools Related Companies Pulmatrix Competitors Cyclo Therapeutics Competitors KALA BIO Competitors CASI Pharmaceuticals Competitors Enlivex Therapeutics Competitors BioAtla Competitors ABVC BioPharma Competitors Clene Competitors ALX Oncology Competitors NanoViricides Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APLM) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street see...Porter & Company | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apollomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy APLM Stock Free APLM Stock Alerts